Previous 10 | Next 10 |
Summary Shares have posted a 40% loss over the past 12 months. I have added confidence in prospects for darovasertib in uveal melanoma given monotherapy activity as well as high ORR and PFS relative to competitors. MAT2A combination with Amgen's PRMT5 inhibitor has a compellin...
Summary Repare Therapeutics' shares have lost roughly half their value over the past year. Roche's deal for ATR inhibitor camonsertib validated the company's SNIPRx and STEP2 platform technologies, a unique take on the emerging field of synthetic lethality. The balance sheet i...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in September. Details for the fir...
Repare Therapeutics press release ( NASDAQ: RPTX ): Q2 GAAP EPS of -$0.91 misses by $0.06 . Revenue of $0.67M (+139.3% Y/Y). For further details see: Repare Therapeutics GAAP EPS of -$0.91 misses by $0.06, revenue of $0.67M
Signed worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib (also known as RP-3500) Repare received a $125 million upfront payment in July 2022 as part of the collaboration agreement with Roche, and is eligible to re...
ARK Invest’s 13F portfolio value decreased from $23.96B to $16.91B this quarter. Coinbase Global, Roku, Shopify, and Ginkgo Bioworks were increased while decreasing Spotify, Ionis Pharma, Vertex Pharma, and Sea Limited. The top three positions are Tesla, Zoom Video, and Rok...
Repare Therapeutics is working in synthetic lethality, where big pharma has shown interest. They have some early data. While things look good, I will wait for more conclusive data before I jump in. For further details see: Repare Therapeutics: Interesting Gene Editing Co...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 43rd Annual Global He...
Repare Therapeutics Inc ( NASDAQ: RPTX ), a top clinical-stage precision oncology corporation, announced that it’s executed a collaboration and worldwide license deal with Roche for both the commercialization and development of RP-3500 (also known as camonsertib). This ne...
Repare Therapeutics (NASDAQ:RPTX) is continuing to benefit Thursday from a licensing deal with Roche (OTCQX:RHHBY) announced after the closing bell Wednesday. In afternoon trading, shares are up ~40%. Under the terms, Repare (RPTX) is receiving $125M in upfront payments and up to $1.2 bi...
News, Short Squeeze, Breakout and More Instantly...
Repare Therapeutics Inc. Company Name:
RPTX Stock Symbol:
NASDAQ Market:
Repare Therapeutics Inc. Website:
Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund Canada NewsWire AEC invests US$7.5M into Amplitude Ventures US$192M Fund II to support the growth of life science startups, establishing a full-time Amplitude presence in ...
Overall response of 18.2% in heavily pretreated patients across gastrointestinal tumors with target alterations regardless of prior irinotecan exposure Prolonged clinical benefit in patients with CRC, with 40% of irinotecan-naïve patients receiving treatment for greater than nine mon...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of th...